OLMA — Olema Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $335.52m
- -$98.57m
- 34
- 37
- 45
- 32
Annual income statement for Olema Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 21.5 | 71.5 | 107 | 105 | 142 |
| Operating Profit | -21.5 | -71.5 | -107 | -105 | -142 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.1 | -71.1 | -105 | -96.7 | -129 |
| Net Income After Taxes | -22.1 | -71.1 | -105 | -96.7 | -129 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.1 | -71.1 | -105 | -96.7 | -129 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -24 | -71.1 | -105 | -96.7 | -129 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.623 | -1.8 | -2.62 | -2.14 | -2.2 |